Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

441
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
441
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

390
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
390
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

347
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
347
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

574
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
574
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

398
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
398
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

320
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
320

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.

Frontiers in endocrinology·2026
Same author

LELN: A Large Language Model-Dynamically Enhanced Learning Network for Patient Similarity Calculation.

IEEE journal of biomedical and health informatics·2026
Same author

A paradigm-level evaluation of deep learning architectures for plant pest and disease recognition under data-scarce field conditions.

Frontiers in plant science·2026
Same author

Promoting Electroreduction of Nitrate to Ammonia in Neutral Media via the Synergistic Effect of Atomically Dispersed Fe, Cu, and Pd Sites.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Does the distal screw location in the Biplane double-supported screw fixation technique affect the risk of subtrochanteric fractures after femoral neck fixation? A finite element analysis.

BMC musculoskeletal disorders·2026
Same author

Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease.

Peptides·2026

Related Experiment Video

Updated: Nov 17, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.5K

Metformin: A Novel Weapon Against Inflammation.

Bo Bai1, Haibo Chen1

  • 1Department of Cardiology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.

Frontiers in Pharmacology
|February 15, 2021
PubMed
Summary

Metformin shows anti-inflammatory effects in preclinical studies, but clinical use for chronic diseases requires more research. Future trials will clarify its potential beyond type 2 diabetes treatment.

Keywords:
chronic diseaseclinical utilizationdebateinflammatinmetformin

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.9K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.5K

Related Experiment Videos

Last Updated: Nov 17, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.5K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.9K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.5K

Area of Science:

  • Pharmacology
  • Immunology
  • Chronic Disease Management

Background:

  • Inflammation is a key factor in chronic diseases like cardiovascular disease, diabetes, and cancer.
  • Current nonsteroidal anti-inflammatory drugs have limited clinical efficacy.
  • Metformin, a widely used type 2 diabetes drug, is being investigated for anti-inflammatory properties.

Purpose of the Study:

  • To review preclinical and clinical evidence of metformin's anti-inflammatory effects.
  • To assess metformin's therapeutic potential in chronic inflammatory conditions beyond type 2 diabetes.

Main Methods:

  • Review of existing scientific literature.
  • Analysis of preclinical data (cell and animal models).
  • Evaluation of clinical trial results and patient data.

Main Results:

  • Metformin demonstrates significant anti-inflammatory effects in preclinical models.
  • Evidence suggests potential therapeutic applications in various inflammatory diseases.
  • Clinical data on repurposing metformin for chronic inflammation is still developing.

Conclusions:

  • Metformin exhibits promising anti-inflammatory properties supported by preclinical research.
  • Clinical application for inflammation-driven chronic diseases requires further investigation and targeted trials.
  • Future randomized controlled trials are needed to establish metformin's efficacy and optimal use in these conditions.